A study to compare  prognostic  utility of procalcitonin with existing biomarkers (CRP and TLC) and clinical risk scores (PSI and CURB 65) in community acquired pneumonia

Sudhir Kumar Agarwal; Manoj Meena; Arvind Kumar Misra; Lalit Prashant Meena; Mrityunjaya Singh

doi:10.5455/njppp.2015.5.120720141

2025, Vol: 15, Issue: 3

15 / 3Current Issue Online First Archive Aims and Scope Abstracting & Indexing Most Accessed Articles Most Downloaded Articles Most Cited Articles

Required files to be uploaded

NJPPP Manuscript Submission Form

« Previous Article

Original Research
Online Published: 18 Jan 2015

Natl J Physiol Pharm Pharmacol. 2015; 5(1): 28-32

doi: 10.5455/njppp.2015.5.120720141

A study to compare prognostic utility of procalcitonin with existing biomarkers (CRP and TLC) and clinical risk scores (PSI and CURB 65) in community acquired pneumonia

Sudhir Kumar Agarwal, Manoj Meena, Arvind Kumar Misra, Lalit Prashant Meena, Mrityunjaya Singh.

Cited By:3

Abstract
Background: Community-acquired pneumonia (CAP) is a leading cause of morbidity and mortality. Biomarkers are increasingly being used to distinguish bacterial pneumonia from other causes, to help reduce the duration of antibiotic therapy, and to assess the prognosis of CAP and thereby aiming to complement Pneumonia Severity Index (PSI) and other scores.

Aims & Objective: To compare prognostic utility of procalcitonin (PCT) with existing biomarkers [C-reactive protein (CRP) and total leukocyte count (TLC)] and clinical risk scores (PSI and CURB-65).

Materials and Methods: Fifty patients diagnosed with CAP were included in this study. Baseline serum PCT was measured, which was then stratified according to four predetermined tiers (tier I: <0.1; tier II: 0.1 to <0.25; tier III: 0.25 to <0.5; tier IV: ≥0.5 μg/L). To calculate the severity of pneumonia, patients were classified according to PCT tier, PSI, and CURB-65 scores. Follow-up PCT and reclassification of PSI and CURB-65 were carried out on days 4 and 30.

Results: PCT was more significantly associated with positive bacterial culture than CRP and TLC. Initial PCT level was significantly correlated with TLC (p = 0.044), CRP (p < 0.001), PSI (p < 0.001), and CURB-65 (p = 0.028).

Conclusion: Findings in our study showed that the management of severe CAP would be greatly improved if it were possible to identify, early in the course of disease, those patients who are most likely to develop complications and are at the risk of mortality.

Key words: Pneumonia; Community-Acquired Pneumonia; Procalcitonin; Biomarkers; Clinical Risk Scores

	ARTICLE TOOLS
	Abstract
	PDF Fulltext
	How to cite this article
	Citation Tools
	Related Records
	Articles by Sudhir Kumar Agarwal Articles by Manoj Meena Articles by Arvind Kumar Misra Articles by Lalit Prashant Meena Articles by Mrityunjaya Singh
	on Google
	on Google Scholar

How to Cite this Article

Pubmed Style

Agarwal SK, Meena M, Misra AK, Meena LP, Singh M. A study to compare prognostic utility of procalcitonin with existing biomarkers (CRP and TLC) and clinical risk scores (PSI and CURB 65) in community acquired pneumonia. Natl J Physiol Pharm Pharmacol. 2015; 5(1): 28-32. doi:10.5455/njppp.2015.5.120720141

Web Style

Agarwal SK, Meena M, Misra AK, Meena LP, Singh M. A study to compare prognostic utility of procalcitonin with existing biomarkers (CRP and TLC) and clinical risk scores (PSI and CURB 65) in community acquired pneumonia. https://www.njppp.com/?mno=161490 [Access: April 17, 2025]. doi:10.5455/njppp.2015.5.120720141

AMA (American Medical Association) Style

Agarwal SK, Meena M, Misra AK, Meena LP, Singh M. A study to compare prognostic utility of procalcitonin with existing biomarkers (CRP and TLC) and clinical risk scores (PSI and CURB 65) in community acquired pneumonia. Natl J Physiol Pharm Pharmacol. 2015; 5(1): 28-32. doi:10.5455/njppp.2015.5.120720141

Vancouver/ICMJE Style

Agarwal SK, Meena M, Misra AK, Meena LP, Singh M. A study to compare prognostic utility of procalcitonin with existing biomarkers (CRP and TLC) and clinical risk scores (PSI and CURB 65) in community acquired pneumonia. Natl J Physiol Pharm Pharmacol. (2015), [cited April 17, 2025]; 5(1): 28-32. doi:10.5455/njppp.2015.5.120720141

Harvard Style

Agarwal, S. K., Meena, . M., Misra, . A. K., Meena, . L. P. & Singh, . M. (2015) A study to compare prognostic utility of procalcitonin with existing biomarkers (CRP and TLC) and clinical risk scores (PSI and CURB 65) in community acquired pneumonia. Natl J Physiol Pharm Pharmacol, 5 (1), 28-32. doi:10.5455/njppp.2015.5.120720141

Turabian Style

Agarwal, Sudhir Kumar, Manoj Meena, Arvind Kumar Misra, Lalit Prashant Meena, and Mrityunjaya Singh. 2015. A study to compare prognostic utility of procalcitonin with existing biomarkers (CRP and TLC) and clinical risk scores (PSI and CURB 65) in community acquired pneumonia. National Journal of Physiology, Pharmacy and Pharmacology, 5 (1), 28-32. doi:10.5455/njppp.2015.5.120720141

Chicago Style

Agarwal, Sudhir Kumar, Manoj Meena, Arvind Kumar Misra, Lalit Prashant Meena, and Mrityunjaya Singh. "A study to compare prognostic utility of procalcitonin with existing biomarkers (CRP and TLC) and clinical risk scores (PSI and CURB 65) in community acquired pneumonia." National Journal of Physiology, Pharmacy and Pharmacology 5 (2015), 28-32. doi:10.5455/njppp.2015.5.120720141

MLA (The Modern Language Association) Style

APA (American Psychological Association) Style

Agarwal, S. K., Meena, . M., Misra, . A. K., Meena, . L. P. & Singh, . M. (2015) A study to compare prognostic utility of procalcitonin with existing biomarkers (CRP and TLC) and clinical risk scores (PSI and CURB 65) in community acquired pneumonia. National Journal of Physiology, Pharmacy and Pharmacology, 5 (1), 28-32. doi:10.5455/njppp.2015.5.120720141

About National Journal of Physiology, Pharmacy and Pharmacology

Contact Information

How to cite this article